Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology develops a single-molecule proteome analysis platform for measuring proteins and proteoforms across the human proteome. Company news centers on the Voyager™ Platform, Iterative Mapping, the Tau Proteoforms assay, early access customer activity, and collaborations that apply isoform-resolved proteomics to cancer and neurodegenerative disease research.
Updates also cover quarterly financial results, operating outlook, commercial-readiness activity, senior sales leadership, scientific conference presentations, and investor-conference participation. The company's disclosures frame Nautilus as a development-stage life sciences tools business moving its proteomics platform from validation and field evaluation toward broader customer access.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced plans to report its financial results for Q2 of fiscal year 2021 on August 10, 2021, before the market opens. A webcast conference call will follow at 5:00 a.m. PT / 8:00 a.m. ET to discuss the results, business developments, and future outlook. Nautilus focuses on pioneering a single-molecule protein analysis platform to advance proteomics, aiming to enhance accessibility to proteomic data and contribute to advancements in human health and medicine.
Nautilus Biotechnology announced the appointment of Dr. Emma Lundberg to its Scientific Advisory Board, effective immediately. Lundberg is a pioneer in spatial proteomics, bringing extensive expertise in human cell biology and artificial intelligence. Her role supports Nautilus's mission to develop a single-molecule protein analysis platform aimed at quantifying the proteome. This strategic addition follows Nautilus's recent public debut, backed by $345 million raised from its business combination with Arya Sciences Acquisition Corp III, aiming to fundamentally enhance biomedical research and diagnostics.
Nautilus Biotechnology completed its business combination with Arya Sciences Acquisition Corp III on June 9, 2021, and will trade under ticker symbol NAUT on the Nasdaq beginning June 10, 2021. The deal generated $345 million in gross proceeds, comprising $145 million from Arya III's trust account and $200 million in PIPE financing. The company aims to revolutionize proteomics with its technology, which could identify over 95% of the proteome using innovative approaches. Led by CEO Sujal Patel and Chief Scientist Parag Mallick, Nautilus is focused on advancing drug development and biomedical research.